Does Medibank Private (ASX:MPL) deserve a place on your watch list?
Like a puppy chasing its tail, some new investors are often looking for “the next big thing,” even if that means buying “history stocks” with no revenue, let alone profit. And in their study titled Who falls prey to the wolf of Wall Street? » Leuz and. al. found that it is “fairly common” for investors to lose money by buying into “pump and dump” schemes.
Contrary to all that, I prefer to spend time on companies like Private Medibank (ASX:MPL), which not only generates revenue, but also profits. Although profit is not necessarily a social good, it is easy to admire a company that can produce it consistently. Conversely, a loss-making business has yet to prove itself with profits, and eventually the sweet milk of outside capital can turn sour.
Discover our latest analysis for Medibank Private
How fast is Medibank Private growing?
If a company can keep increasing its earnings per share (EPS) long enough, its stock price will eventually follow. Therefore, there are many investors who like to buy shares in companies that grow EPS. Over the past three years, Medibank Private has grown EPS by 5.1% per year. Although this type of growth rate is not surprising, it shows that the company is growing.
One way to check a company’s growth is to look at the evolution of its revenues and its earnings before interest and taxes (EBIT) margins. I note that the income from Medibank Private operations was lower than its turnover in the last twelve months, which could distort my analysis of its margins. While we note that Medibank Private’s EBIT margins have remained stable over the past year, revenues increased by 4.4% to A$7.1 billion. This is a real plus point.
You can check the company’s revenue and profit growth trend in the table below. To see the actual numbers, click on the chart.
You don’t drive with your eyes on the rearview mirror, so you might be more interested in that free report showing analyst forecasts for Medibank Private to come up profits.
Are Medibank private insiders aligned with all shareholders?
Generally, I think it’s worth considering how much the CEO gets paid, because unreasonably high rates could be considered against the interests of shareholders. For companies with a market capitalization between AU$5.5 billion and AU$17 billion, such as Medibank Private, the median CEO salary is around AU$3.4 million.
Medibank Private offered total compensation worth A$2.1 million to its CEO during the year at . This is below average for companies of a similar size and seems pretty reasonable to me. CEO compensation isn’t the most important aspect of a company to consider, but when it’s reasonable, it gives me a bit more confidence that executives are looking out for shareholders’ interests. It can also be a sign of good governance more generally.
Does Medibank Private deserve a spot on your watch list?
A plus point for Medibank Private is that it increases EPS. It’s nice to see. On top of that, my confidence in the board is bolstered by the fact that the CEO’s reasonable compensation. So overall, I think it’s at least worth considering for your watchlist. It is still necessary to take into account the risks, for example – Medibank Private has 1 warning sign we think you should know.
You can invest in the company of your choice. But if you’d rather focus on stocks that have been insider buying, here’s a list of companies that have been insider buying over the past three months.
Please note that insider trading discussed in this article refers to reportable trading in the relevant jurisdiction.
Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.